Abstract
Soluble oligomers of the amyloid-β peptide (AβOs) accumulate in Alzheimers disease (AD) brain and have been implicated in mechanisms of pathogenesis. The neurotoxicity of AβOs appears to be, at least in part, due to dysregulation of glutamate signaling. Here, we show that AβOs promote extracellular accumulation of glutamate and D-serine, a co-agonist at glutamate receptors of the N-methyl-D-aspartate subtype (NMDARs), in hippocampal neuronal cultures. The increase in extracellular glutamate levels induced by AβOs was blocked by the sodium channel blocker tetrodotoxin (TTX), by the NMDAR blocker (+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate (MK-801) and by removal of Ca2+ from the extracellular medium, indicating dependence on excitatory neuronal activity. AβOs enhanced the release of pre-synaptic vesicles labeled by FM1-43 as well as spontaneous post-synaptic activity measured by whole-cell patch-clamp. Activation of inhibitory GABAA receptors by taurine blocked the increase in extracellular glutamate levels, suggesting that selective pharmacological inhibition of neuronal activity can counteract the impact of AβOs on glutamate dyshomeostasis. Results reveal a novel mechanism by which Aβ oligomers promote abnormal release of glutamate from hippocampal neurons, which may contribute to dysregulation of excitatory signaling in the brain.
Keywords: Aβ oligomers, Alzheimer's disease, D-serine, glutamate, taurine, Aβoligomers, excitatory synapses, Hippocampal Slices, glial cells
Current Alzheimer Research
Title: Aβ Oligomers Induce Glutamate Release from Hippocampal Neurons
Volume: 8 Issue: 5
Author(s): J. Brito-Moreira, A. C. Paula-Lima, T. R. Bomfim, F. F. Oliveira, F. J. Sepulveda, F. G. De Mello, L. G. Aguayo, R. Panizzutti and S. T. Ferreira
Affiliation:
Keywords: Aβ oligomers, Alzheimer's disease, D-serine, glutamate, taurine, Aβoligomers, excitatory synapses, Hippocampal Slices, glial cells
Abstract: Soluble oligomers of the amyloid-β peptide (AβOs) accumulate in Alzheimers disease (AD) brain and have been implicated in mechanisms of pathogenesis. The neurotoxicity of AβOs appears to be, at least in part, due to dysregulation of glutamate signaling. Here, we show that AβOs promote extracellular accumulation of glutamate and D-serine, a co-agonist at glutamate receptors of the N-methyl-D-aspartate subtype (NMDARs), in hippocampal neuronal cultures. The increase in extracellular glutamate levels induced by AβOs was blocked by the sodium channel blocker tetrodotoxin (TTX), by the NMDAR blocker (+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate (MK-801) and by removal of Ca2+ from the extracellular medium, indicating dependence on excitatory neuronal activity. AβOs enhanced the release of pre-synaptic vesicles labeled by FM1-43 as well as spontaneous post-synaptic activity measured by whole-cell patch-clamp. Activation of inhibitory GABAA receptors by taurine blocked the increase in extracellular glutamate levels, suggesting that selective pharmacological inhibition of neuronal activity can counteract the impact of AβOs on glutamate dyshomeostasis. Results reveal a novel mechanism by which Aβ oligomers promote abnormal release of glutamate from hippocampal neurons, which may contribute to dysregulation of excitatory signaling in the brain.
Export Options
About this article
Cite this article as:
Brito-Moreira J., C. Paula-Lima A., R. Bomfim T., F. Oliveira F., J. Sepulveda F., G. De Mello F., G. Aguayo L., Panizzutti R. and T. Ferreira S., Aβ Oligomers Induce Glutamate Release from Hippocampal Neurons, Current Alzheimer Research 2011; 8 (5) . https://dx.doi.org/10.2174/156720511796391917
DOI https://dx.doi.org/10.2174/156720511796391917 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Acanthamoeba-Bacteria: A Model to Study Host Interaction with Human Pathogens
Current Drug Targets Long-Term CD4 Cell Count Recovery among Thai Naive HIV-Infected Patients Initiating HAART at Low CD4 Cell Count
Current HIV Research Calpain Inhibition: A Therapeutic Strategy Targeting Multiple Disease States
Current Pharmaceutical Design Drug Targeting Approaches and Use of Drug Delivery Systems in Management of Cancer
Current Pharmaceutical Design Water and Ion Channels: Crucial in the Initiation and Progression of Apoptosis in Central Nervous System?
Current Neuropharmacology Blood-Brain Barrier Transport of Cytokines: A Mechanism for Neuropathology
Current Pharmaceutical Design Neuroleptic Malignant Syndrome: A Pilot Study on Psychiatric Inpatients in Iran
Current Psychopharmacology Infection and Anemia
Infectious Disorders - Drug Targets Pregnancy Associated Brucellosis
Recent Patents on Anti-Infective Drug Discovery Aptamers: Molecular Tools for Medical Diagnosis
Current Topics in Medicinal Chemistry Newer Avenues for the Treatment of Leptomeningeal Carcinomatosis
Central Nervous System Agents in Medicinal Chemistry Conventional and Gene Therapy Strategies for the Treatment of Brain Tumors
Current Medicinal Chemistry A Review on Hematopoietic Stem Cell Treatment for Epilepsy
CNS & Neurological Disorders - Drug Targets Clinical Significance of Cytokines and Chemokines in Neuropsychiatric Systemic Lupus Erythematosus
Current Rheumatology Reviews CT and MR Imaging of the Encephalopathic Child
Current Medical Imaging Recent Developments in the Synthesis and Biological Activity of Muramylpeptides
Current Medicinal Chemistry Substance P in Rheumatic Diseases
Current Rheumatology Reviews Recent Patents Concerning Modulators of Protein Kinase C
Recent Patents on DNA & Gene Sequences Epidemiology and Management of Infectious Complications in Contemporary Management of Chronic Leukemias
Infectious Disorders - Drug Targets Central G-Protein Coupled Receptors (GPCR)s as Molecular Targets for the Treatment of Obesity: Assets, Liabilities and Development Status
Current Drug Targets - CNS & Neurological Disorders